



U. S. Department of Justice
Drug Enforcement Administration

www.dea.gov

Washington, D.C. 20537

MAY 0 2 2007

Dear Colleague:

On May 3, 2007, the Drug Enforcement Administration (DEA) published in the *Federal Register* a Final Rule to place the central nervous system stimulant substance lisdexamfetamine, including its salts, isomers, and salts of isomers, into schedule II of the Controlled Substances Act (CSA). This rule will become effective June 4, 2007.

This action is based on a recommendation from the Assistant Secretary for Health of the Department of Health and Human Services and on an evaluation of the relevant data by the DEA. Lisdexamfetamine shares substantial pharmacological effects and abuse potential with amphetamine. Since lisdexamfetamine is a prodrug for d-amphetamine, which is known to cause both psychological and physical dependence, it is expected to possess dependence potential similar to that of d-amphetamine. Lisdexamfetamine will be marketed as a prescription drug product for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

This rulemaking is available at the Diversion Control Program web site
<http://www.DEAdiversion.usdoj.gov>.

Sincerely,

A handwritten signature in black ink, appearing to read "Mark W. Caverly".

Mark W. Caverly, Chief
Liaison and Policy Section
Office of Diversion Control